Hematologic and biochemical characteristics in patients with and without type 2 diabetes mellitus undergoing hemodialysis during a one-year follow-up period

• Autores: Alvarez-Angeles, M., Torres-Palomino, D., Guadalupe-Gomez, H., Delgado-Bocanegra, M. I., Arrunategui-Correa, V.
• Formato: artículo
• Fecha de Publicación: 2018
• Institución: Universidad de San Martín de Porres
• Repositorio: Horizonte médico
• Lenguaje: español
• OAI Identifier: oai:horizontemedico.usmp.edu.pe:article/771
• Enlace del recurso: https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/771
• Nivel de acceso: acceso abierto
• Materia: Type 2 diabetes mellitus; Metabolism; Hemodialysis; Blood; Immunology; Diabetes mellitus tipo 2; Metabolismo; Hemodiálisis; Sangre; Inmunología

Objective: To report if there are hematologic and biochemical differences among patients with and without type 2 diabetes mellitus (T2DM) undergoing hemodialysis (HD). Materials and methods: An observational, retrospective, cohort study of patients treated in the Renal Health Program at the Centro de Prevención de Enfermedad Renal S.A.C. (CENPER) in Lima, Peru. The hematologic and biochemical parameters of 3 patients with T2DM and 3 patients without T2DM undergoing HD were compared. Results: Significant differences (p < 0.05) were found in the lymphocyte percentage, lymphocyte/monocyte ratio (LMR), hemoglobin and hematocrit concentration (lower in diabetic patients), monocyte percentage, and neutrophil/ lymphocyte ratio (NLR) (higher in diabetic patients). In the biochemical parameters, the only significant difference was found in the glutamic-oxaloacetic transaminase (GOT) value, which was higher in the diabetic patients compared with the non-diabetic patients (p < 0.005). Conclusions: Diabetes is an important factor linked to inflammation, anemia, lymphopenia and monocytosis in patients undergoing HD. The LMR was the most powerful marker of inflammation in this patient series. Larger-scale studies are required to verify this evidence.